Auris Medical is behind AM-101 and AM-101 is a drug currently in Phase IIb trial. It's a possible future treatment for tinnitus originating in the inner ear.
The U.S. Study details are here: http://clinicaltrials.gov/ct2/show/NCT00860808
There are lots of more info on AM-101 here on Auris Medical's own site:
http://www.aurismedical.com/product-candidates/am-101
As always, I'm very much looking forward to the results from the trials. So far it's not really 100% certain how long the window of administration is after the onset of tinnitus. The trials exclude people who have had tinnitus for longer than 3 months, but it doesn't necessarily mean the drug won't work for tinnitus cases that are, say, 6 months old?
Correct me if I'm wrong, but it is thought the permanent brain changes occur only after some time, not directly after noise exposure and onset of tinnitus.
If you happen to be a participant in the AM-101 trial, it would be super cool if you shared your experience.
Otherwise feel free to discuss what you think of it.
The U.S. Study details are here: http://clinicaltrials.gov/ct2/show/NCT00860808
Auris Medical announced today that enrollment has started for its phase II clinical trial with AM-101 for the treatment of acute inner ear tinnitus. The study will enroll a total of 24 patients for further evaluation of the optimum dosing regimen for AM-101 as well as to generate additional pharmacokinetic data. The inclusion criteria require among others that the tinnitus was triggered by an incident of acute noise trauma, sudden deafness, otitis media, inner ear barotrauma or middle ear surgery not more than three months ago. Study participants will receive either AM-101 at 0.81 mg/ml or placebo in a single or triple dose intratympanic injection. Recruitment for the study is expected to be completed before the end of this year.
AM-101 contains a small molecule that selectively blocks N-methyl-D-aspartate (NMDA) receptors. Emerging evidence suggests that NMDA receptors in the cochlea play a major role in the occurrence of tinnitus following inner ear excitotoxicity, which is characterized by excessive synaptic release of glutamate, the principal neurotransmitter in the auditory system. Cochlear excitotoxicity may be triggered by, for example, exposure to excessive noise, disturbances in inner ear blood supply (anoxia/ischemia), barotrauma, migration of pathogens from the inflamed middle ear into the inner ear, noise/vibration trauma resulting from middle ear surgery or the administration of certain ototoxic drugs. It has been hypothesized that the upregulation of NMDA receptors induced by cochlear excitotoxicity is responsible for abnormal spontaneous "firing" of auditory nerve fibres, which is perceived as tinnitus.
A first clinical trial with AM-101 (phase I/II) showed that intratympanically injected AM-101 was well tolerated by study participants and provided the first indications of therapeutic efficacy. A large double-blind, randomised, placebo-controlled phase IIb clinical trial with AM-101 is currently under way in Germany, Belgium, Poland and the Netherlands to further evaluate the treatment's efficacy and safety. Patient enrollment in the study was completed in early February 2011.
There are lots of more info on AM-101 here on Auris Medical's own site:
http://www.aurismedical.com/product-candidates/am-101
As always, I'm very much looking forward to the results from the trials. So far it's not really 100% certain how long the window of administration is after the onset of tinnitus. The trials exclude people who have had tinnitus for longer than 3 months, but it doesn't necessarily mean the drug won't work for tinnitus cases that are, say, 6 months old?
Correct me if I'm wrong, but it is thought the permanent brain changes occur only after some time, not directly after noise exposure and onset of tinnitus.
If you happen to be a participant in the AM-101 trial, it would be super cool if you shared your experience.
Otherwise feel free to discuss what you think of it.